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Acute leukemia relapsing after chemotherapy plus allogeneic hematopoietic stem cell
transplantation can be treated with donor-derived T cells, but this is hampered by the need
for donor/recipient MHC-matching and often results in graft-versus-host disease, prompting
the search for new donor-unrestricted strategies targeting malignant cells. Leukemia blasts
express CD1c antigen-presenting molecules, which are identical in all individuals and
expressed only by mature leukocytes, and are recognized by T cell clones specific for the
CD1c-restricted leukemia-associated methyl-lysophosphatidic acid (mLPA) lipid antigen.
Here, we show that human T cells engineered to express an mLPA-specific TCR, target
diverse CD1c-expressing leukemia blasts in vitro and significantly delay the progression of
three models of leukemia xenograft in NSG mice, an effect that is boosted by mLPA-cellular
immunization. These results highlight a strategy to redirect T cells against leukemia via
transfer of a lipid-specific TCR that could be used across MHC barriers with reduced risk of
graft-versus-host disease.
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Acute leukemia is a heterogeneous group of hematologicalcancers that all involve malignant proliferation ofimmature hematopoietic cells which invade the bone
marrow, blood, and extramedullary sites, and can affect a wide
range of age groups with varying degrees of severity. The most
common adult and pediatric types are acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL), respectively,
with an incidence of about 4 cases/100,000 in the western world1.
Current treatment for low-risk acute leukemia consists of several
courses of chemotherapy; whereas intermediate/high-risk diseases
need subsequent consolidation with allogeneic hematopoietic
stem cell transplantation (HSCT). Although many acute leukemia
patients achieve complete remission, approximately 20–30%
eventually undergo disease relapses. These patients have a very
poor prognosis, and effective treatments targeting the post-
transplant recurrence of residual leukemia blasts is a major unmet
clinical need2. One approach is the transfer of allogeneic donor-
derived T cells, which may induce a beneficial graft-versus-
leukemia (GvL) reaction capable of maintaining remission3.
However, the grafted allogeneic T cells can also attack patients’
non-hematopoietic tissues, inducing detrimental graft-versus-
host disease (GvHD)4. To avoid this risk it is necessary to develop
a T cell-mediated therapeutic strategy targeting malignant cells,
while maintaining hematopoietic capacity among grafted cells
and preserving organ functions in recipient patients3. T cells
specific for tumor-derived peptide antigens presented by MHC
molecules have a critical role in controlling cancer progression5,
and ex vivo engineering of T cells with MHC-restricted T cell
receptors (TCR) specific for peptides derived from tumor anti-
gens has the potential to generate large numbers of tumor-specific
effector T cells from a patient5. However, because of the high
polymorphism of MHC, this approach requires the isolation of
many different tumor-specific TCRs restricted to the most fre-
quent HLA alleles.
An alternative strategy is T cell-mediated targeting of tumor
antigens presented by monomorphic molecules, such as CD1
and MR1. CD1 molecules are MHC class I-related molecules
specialized in presenting lipid antigens6, and humans express
five CD1 genes: CD1a, CD1b and CD1c (group 1); CD1d (group
2); and CD1e (group 3). CD1-restricted T cells recognize for-
eign lipids from pathogenic bacteria7, but are also strongly
reactive against specific cell-endogenous “self” lipids7. These
CD1 self-reactive T cells constitute 0.1 to 10% of circulating
T lymphocytes8,9, and their role in the immune response is
incompletely understood. Group 1 CD1 molecules are expres-
sed only by mature hematopoietic cells6, and their expression is
elevated in leukemia and lymphoma cells; indeed, CD1c is
detected on all the blasts of 54% of adult and 45% of pediatric
AML patients, and on all the blasts of 71% of adult and 26% of
pediatric B cell acute lymphoblastic leukemia10. Furthermore, a
group of CD1c self-reactive T cell clones that recognizes
methyl-lysophosphatidic acid (mLPA), a novel lipid antigen
that is highly enriched in leukemia cells compared to healthy
leukocytes has been identified10; these T cells killed leukemia
blasts in vitro and in immunodeficient mouse xenograft
models10. These data led us to investigate whether generating
CD1c-retargeted allogeneic T cells recognizing mLPA expressed
by leukemia cells might represent a novel immunotherapy able
to overcome the limitation of conventional MHC-restricted T
cell therapies for leukemia.
CD1c-restricted T cells specific for mLPA are potentially ideal
candidates for the adoptive immunotherapy of acute leukemia
due to the following unique characteristics: (i) CD1c is not
polymorphic6, allowing the generation of donor-unrestricted
(universal) effector T cells; (ii) CD1c is not expressed by par-
enchymatous organs6, minimizing the risk of eliciting GvHD; (iii)
mLPA is highly enriched in malignant cells, but not in normal
cells10; and (iv) mLPA belongs to lipid species participating in the
oncogenic process and tumor progression10,11 that, being pro-
duced through complex synthetic pathways, may also be less
susceptible than protein antigens to immune-mediated loss
caused by single gene mutation.
In this work, we transduce a range of mLPA-specific TCRs
into human T cell lines and primary human T cells in order to
identify a lead candidate for preclinical testing. We show that
transduction with the selected lead mLPA-specific TCR effi-
ciently retargeted polyclonal T cells from a range of donors
against CD1c-expressing acute leukemia cells in vitro, while
sparing healthy CD1c-expressing circulating monocytes, Den-
dritic Cells (DC) and B cells. When we transfer these TCR-
expressing T cells into acute leukemia xenograft mouse models
we show evidence of tumor infiltration, inhibited tumor growth,
and prolonged survival.
Results
CD1c is expressed in AML, B-ALL and DLBCL. CD1c expres-
sion on blasts from two cohorts of pediatric and adult acute
leukemia patients had been previously detected by flow
cytometry10. To confirm and extend these original findings, we
first established the expression levels of all group 1 and 2 CD1
genes in acute leukemia by interrogating 16 publicly available
gene expression datasets from adult and pediatric AML, B-ALL,
and T cell acute lymphoblastic leukemia (T-ALL) patients
(Supplementary Table 1). These datasets were filtered according
to uniformity of platforms, e.g. Affymetrix, completeness of
available clinical information and with adequate number of
samples for each leukemia type. This analysis revealed that CD1c
was the most abundantly expressed member of the CD1 family in
both AML and B-ALL (Fig. 1a, Supplementary Fig. 1a), con-
firming our previous findings. The GSE18497 dataset, the only
one available with matched diagnosis-relapse paired samples,
reported comparable levels of CD1 gene expression in B-ALL and
T-ALL at diagnosis and at relapse (Fig. 1b), supporting the
immunological targeting of CD1 molecules at both early and late
stages of these malignancies. When we extended our analysis to
evaluating CD1c expression in a broad range of tumor types using
the Cancer Genome Atlas (TCGA), we also found significant
overexpression in Diffuse Large B Cell Lymphoma (DLBCL)
compared to normal tissue (Fig. 1c, Supplementary Table 2).
Thus, CD1c-reactive T cells have the potential to target AML, B-
ALL, T-ALL, and DLBC lymphoma expressing CD1c.
Selection of optimal CD1c tumor-reactive TCR for leukemia
targeting. Having established that CD1c was abundantly
expressed in acute leukemias and DLBCL, the next step was to
identify the optimal CD1c-restricted TCR to retarget T cells
against these malignancies. We therefore selected five CD1c self-
reactive T cell clones10 and sequenced their TCR α and β genes:
each T cell clone expressed a unique TCR, some sharing V
regions, but always with diverse junctional sequences (Supple-
mentary Fig. 1b). We then cloned the cDNA sequence encoding
the TCR Vα and Vβ chains of each TCR into a lentiviral vector
(LV) (Supplementary Fig. 1c). The human Vα and Vβ regions
were joined to the respective mouse C regions (as described12) to
avoid mispairing of the transduced TCR with the endogenous
chains in the transduced T cells, and to increase the expression of
the transduced TCR. We selected Jurkat 76 cells as the trans-
duction target because they do not express an endogenous TCR13;
however, these cells normally express all CD1 molecules, so to
avoid any CD1c-dependent homotypic recognition by the TCR-
transduced cells, we deleted the B2M gene with CRISPR/Cas9
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technology to prevent endogenous CD1 expression, prior to TCR
transfer6 (Supplementary Fig. 1d, e). Flow cytometry detection of
the transduced chimeric TCRs by anti-mouse TCR Cβ mono-
clonal antibody (mAb) showed that four TCRs (DN4.99,
PZP8A6, DN4.2, and P8E3) were efficiently expressed on the
surface of the transduced Jurkat 76 β2m- cells (Fig. 2a).
We next asked whether TCR-transduced Jurkat 76 β2m- (TCR-
JK) cells could recognize AML cell lines engineered to express
CD1c (Fig. 2b), and loaded or not loaded with synthetic mLPA.
The DN4.99, PZP8A6, and DN4.2 TCR-JK cells expressed
significantly higher levels of the activation marker CD69
following co-culture with CD1c-expressing THP-1 (Fig. 2c) or
K562 (Fig. 2d) cells compared to WT, and their activation was
further significantly increased in the presence of mLPA. Although
the P8E3 TCR was detected at the JK cell surface (Fig. 2a), P8E3
TCR-JK cells did not show activation in response to either AML
cell line (Fig. 2c, d); interestingly, the P8E3 TCR shares the same
Vα/Vβ genes as DN4.99 TCR (Supplementary Fig. 1b), but has
different rearrangements, suggesting that the TCR CDR3 regions
are important for recognition of mLPA. When we compared the
reactivity of the DN4.99, PZP8A6 and DN4.2 TCR-JK cells
against different doses of mLPA presented on K562-CD1c cells
we found that, despite very similar levels of surface expression,
the DN4.99 TCR exhibited a lower EC50 (half-maximal effective
concentration) than the other two TCRs, and the highest CD69
expression (Fig. 2e), suggesting stronger functional avidity14,15
upon antigen engagement.
Next, we transduced the chimeric DN4.99, PZP8A6, and
DN4.2 TCRs into freshly isolated circulating T cells from healthy
donors (n = 3–5) and measured their expression and ability to
recognize mLPA. All three TCRs were expressed on at least 70%
of transduced T cells (Fig. 3a), but DN4.99 TCR induced the
strongest and most sustained (up to 27 days post-transduction)
downregulation of endogenous TCRs (Fig. 3b, Supplementary
Fig. 2a). This is consistent with published reports showing a
higher affinity of mouse TCR Cα and Cβ regions for the human
CD3ζ compared to the human C regions12, resulting in the
sequestration of available CD3ζ molecules, which are the rate-
limiting components for the transport of all TCR/CD3 complexes
to the cell membrane16,17 by the transduced chimeric TCRs.
The strong downregulation of the endogenous TCRs by the
DN4.99 TCR is a characteristic that might improve the safety of
adoptive cell therapy (ACT) in allogeneic HSCT, by reducing the
Fig. 1 CD1 gene expression in leukemia datasets. Analysis of group 1 and
group 2 CD1 expression levels in different types of leukemia from
published datasets highlights higher and more uniform expression of
CD1c in both adult and pediatric Acute Myeloid Leukemia (AML) and
B-Acute Lymphoblastic Leukemia (B-ALL). a Expression level of CD1
genes across a selection of leukemia datasets [adult AML: GSE12417;
pediatric AML: GSE17855; adult B-ALL: GSE14834; pediatric B-ALL:
GSE13576; adult T-Acute Lymphoblastic Leukemia (T-ALL): GSE14618;
pediatric T-ALL GSE50999; the expression levels of CD1 genes in
additional datasets are reported in Supplementary Fig. 1a]. Sample size of
each dataset is detailed in Supplementary Table 1. b Elevated expression
of CD1c in adult B-ALL is preserved in patients not responding to
therapies, while its expression remains low in T-ALL at the time of
diagnosis and at relapse. Data were obtained from GSE18497 leukemia
dataset. Sample size of the dataset is detailed in Supplementary Table 1.
c CD1c expression in TCGA-AML and TCGA-Diffuse Large B Cell
Lymphoma (DLBCL) tumor samples (T) compared to their corresponding
normal tissues (N). The analysis included 173 AMLs and 70 normal bone
marrow samples, and 47 DLBCLs and 337 normal blood samples
(Table S2). Data on tumor samples were obtained from TCGA, while
normal sample data were obtained from GTEx. CD1c expression was
considered significant at *P < 1.00E−10 in a one-way ANOVA. In the box
plots, the box is enclosed between the first quartile (25th percentile) and
the third quartile (75th percentile), the center is represented by the
median, the whiskers are defined by 1.5 times the interquartile range (i.e.,
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expression of potentially alloreactive TCRs implicated in the
pathogenesis of GvHD, although additional strategies to prevent
GvHD by TCR-T cells are warranted for clinical application. The
expanded TCR-transduced and non-transduced T cells reprodu-
cibly contained mixed central memory, effector memory, terminal
effector, and CD95+ stem cell memory populations (Supplemen-
tary Fig. 2b, c), as expected by the action of IL-7 and IL-15 in
culture18. We then tested the mLPA-specific TCR-transduced
primary T cells (TCR-T cells) for their ability to recognize CD1c-
expressing AML cell lines in vitro. DN4.99, PZP8A6, and DN4.2
TCR-T cells secreted IFN-γ in the presence of THP-1-CD1c, but
not of THP-1 WT cells, in contrast to non-transduced T cells
(Fig. 3c).
Taken together, these data identified DN4.99 as the lead TCR
for further development due to its high level of expression,
strongest endogenous TCR repression, strongest reactivity against
CD1c-expressing leukemia cells and mLPA specificity.
DN4.99 TCR-T cells recognize and kill human leukemia cells
in vitro. We next assessed the breadth of reactivity of DN4.99
TCR-T cells against a panel of cell lines representing AML (THP-
1, MOLM-13, K562), ALL (NALM-6, CCRF-SB, MOLT-4), and B
lymphoblastoid cells (C1R), which expressed at different levels
natural or transduced CD1c (Fig. 4a). After 48 h of co-culture
with cell lines, DN4.99 TCR-T cells had secreted significantly
more IFN-γ than non-transduced T cells, and this effect was
dependent on CD1c (Fig. 4b). Similarly, in 1:1 effector:target (E:
T) co-cultures, DN4.99 TCR-T cells had almost completely
eliminated the target cell lines after 72 h, dependent on CD1c,
while target cells remained abundant in co-cultures with non-
transduced T cells (Fig. 4c–e). Because the DN4.99 TCR-T cell
populations contained both CD4+ and CD8+ subsets, we assessed
the relative cytokine production and killing ability of either subset
by sorting and comparing them against THP-1-CD1c cells. We
found that both T cell subsets were polyfunctional, with CD4+
cells producing a larger panel of Th1 and Th2 cytokines (Sup-
plementary Fig. 3a–c). Both subsets eliminated the target cells
but, as expected, CD8+ T cells were significantly more efficient at
the lower E:T ratios of 1:5 and 1:10 (Supplementary Fig. 3d), also
in eliminating MOLM-13 cells that express a lower CD1c level
(Supplementary Fig. 3e).
Next, we asked whether DN4.99 TCR-T cells could recognize
and kill primary CD1c+ leukemia blasts (Fig. 5a). Clinical
evidence with CD19 chimeric antigen receptor (CAR)-T cell
therapy in B cell malignancies, suggests that optimal efficacy was
obtained by the transfer of a 4:1 mixture of CD8+ and CD4+
transduced T cells19, owed to helper cytokine production
by CD4+ T cells. Therefore, in light of the cytokine and
DN4.99 TCR EC50: 239 pg/ml 
PZP8A6 TCR EC50: 339 pg/ml













1.0 1.5 2.0 2.5 3.0 3.50.50
+ K562-CD1c + K562-WT 


















mLPA: + +- - + +- - + +- - + +-- + +--



















mLPA: + +- - + +- - + +- - + +-- + +--
DN4.99 TCR-JK PZP8A6 TCR-JKc
+ THP-1-CD1c + THP-1-WT 






































TCR-Jurkat 76 β2m- cells Jurkat 76 β2m- cells
a
Fig. 2 Identification of the lead CD1c-restricted mLPA-specific TCR to target acute leukemia. Chimeric human V-mouse C TCR chains obtained from the
indicated CD1c self-reactive T cell clones10 followed by IRES and the GFP-coding sequence were cloned into lentivectors and transduced into Jurkat (JK)
cells. Transduced JK cells were sorted to have comparable TCR expression. a TCR expression on transduced (black histograms) and non-transduced (white
histograms) JK cells determined by flow cytometry labeling with anti-mouse TCRβ (mTCRβ) monoclonal antibody (mAb). Relative fluorescence Intensity
(RFI) was calculated as the ratio between the intensity of labeling on transduced and non-transduced JK cells. b Flow cytometry detection of CD1c
expression on CD1c+ (black histograms) and wt (gray histograms) THP-1 and K562 cells labeled with anti-human CD1c mAb. White histograms represent
labeling with isotype-matched control mAb. c, d TCR-JK cells recognize CD1c+ leukemia cells. TCR-JK cells were cultured overnight with THP-1-CD1c (c) or
K562-CD1c (d) leukemia cells ± 1.5 ng/ml of methyl-lysophosphatidic acid (mLPA, black bars), at Effector:Target (E:T) ratio of 2.5:1 (c) or 1:1 (d). Wild-type
(WT) cells were used as a negative control (gray bars). JK cell activation was assessed as increased CD69 expression intensity as measured by flow
cytometry (Mean Fluorescence Intensity, MFI, reported). Data are represented as mean ± SD. Results are representative of 2 (c) and 4 (d) independent
experiments with n = 3 independent replicates per experiment. **P = 0.0023; ***P = 0.004; ****P < 0.0001 determined by Ordinary one-way ANOVA
followed by Tukey’s multiple comparison test. e mLPA recognition by the DN4.99 (red dots), PZP8A6 (black triangles) and DN4.2 (gray squares) TCR-JK
cells, cultured overnight at 1:1 E:T ratio with K562-CD1c cells loaded with serial dilutions of mLPA. CD69 expression intensity on JK cells was then
measured by flow cytometry. The interpolation curves of CD69 expression on TCR-JK cells in response to the indicated mLPA concentration are shown.
EC50 values were obtained as detailed in Methods. Data are represented as mean ± SEM. Results are representative of 3 independent experiments with n =
3 independent replicates per experiment.
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killing results we obtained (Supplementary Fig. 3a–e), for these
experiments we used a mixture of 70% CD8+/30% CD4+
DN4.99 TCR-T cells. Furthermore, we also increased the E:T
ratio to 5–10:1, because primary leukemia blasts are more
resistant to killing than cell lines. DN4.99 TCR-T cells
specifically recognized all 9 blasts freshly isolated from the
blood of patients, as indicated by CD1c-dependent IFN-γ
secretion after 48 h of co-culture (Fig. 5b), and killed between 20
and 80% of the 6 primary leukemic blasts that could be assessed
after 48 h of co-culture (Fig. 5c, d). Both recognition and killing
were significantly reduced by the addition of anti-CD1c mAb.
Thus DN4.99 TCR-T cells could recognize and kill all tested
primary CD1c+ AML and B-ALL blasts, further supporting the
potential for ACT based on this TCR.
DN4.99 TCR-T cells do not kill normal circulating CD1c+
cells. CD1c is expressed by normal circulating B cells, CD14+
monocytes, and CD11c+ DCs (a mixed cDC2/cDC3 and moDC
population)6,20, representing potential additional targets of
DN4.99 TCR T-cells. To assess the risk of unwanted recognition
of these cells, we isolated each population from eight independent
healthy donors, loaded them or not with synthetic mLPA, and co-
cultured them for 72 h with DN4.99 TCR-T cells at an E:T ratio
of 1:1. Despite their expression of intermediate-high levels of
CD1c (Fig. 6a–c), none of the cell populations were killed by
DN4.99 TCR-T cells, unless monocytes and DCs were loaded
with synthetic mLPA (Fig. 6d). This is consistent with our pub-
lished data showing that these circulating leukocytes poorly sti-
mulate CD1c self-reactive T cell clones because of their reduced
mLPA content, in contrast to their malignant counterparts10. We
saw similar results when a mixture of 70% CD8+/30% CD4+
DN4.99 TCR-T cells was used at an E:T ratio of 5:1 (Fig. 6e).
DN4.99 TCR-T cells, therefore, spare healthy CD1c-expressing
cells whilst effectively targeting CD1c-expressing leukemia blasts
ex vivo, supporting the further preclinical investigation of cell
therapy based on this TCR.
ACT with DN4.99 TCR-T cells delays leukemia progression in
mice. Having demonstrated potent CD1c-expressing leukemia-
cell specific cytotoxicity of DN4.99 TCR-T cells, we next assessed
DN4.99 TCR-T cell in vivo antitumor activity in mice injected
with human acute leukemia-cell lines (THP-1, NALM-6, MOLM-
13) stably transduced to express CD1c. The cell lines were also
engineered to express a secreted luciferase to enable non-invasive
monitoring of tumor progression by measuring the ex vivo bio-
luminescence of serum samples21. Furthermore, we selected these
cell lines to test the DN4.99 TCR-T cells against a diverse selec-
tion of pathological features and levels of aggression, representing
the acute leukemia spectrum: following intravenous (i.v.) injec-
tion into NOD.Cg-Prkdcscid IL- 2rgtm1Wjl/SzJ (NSG) mice, the
THP-1 AML cell line, which is the least aggressive, generates liver
myeloid sarcomas, while the NALM-6 B-ALL and MOLM-13
AML cell lines home to the bone marrow and are of relatively
moderate and high aggressiveness, respectively22–24.
First, we injected 1 × 106 THP-1-CD1c cells i.v. into NSG mice
that, after tumor engraftment confirmed by their serum luciferase
levels, were randomized into three groups, and sub-lethally
irradiated, followed 24 h later by the transfer i.v. of 1 × 107
DN4.99 TCR-T cells (70% CD8+/30% CD4+), the same number
of T cells (70% CD8+/30% CD4+) from the same donor
undergoing parallel activation and expansion but no TCR
transduction, or vehicle only (Fig. 7a). DN4.99 TCR-T cell
transfer significantly delayed leukemia progression (Fig. 7b) and
conferred a significant advantage in overall animals’ survival
(Fig. 7c) compared to non-transduced T cell transfer. The livers
of mice receiving DN4.99 TCR-T cells were significantly smaller
than controls (Fig. 7d), due to reduced THP-1 myeloid sarcoma
infiltration, and contained transferred T cells (Fig. 7e). This
experiment showed that DN4.99 TCR-T cells could localize
within human leukemia-bearing mouse livers, reduce tumor
growth and prolong mouse survival. Notably, in the absence of
high tumor burden, none of mice that received DN4.99 TCR-T
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Fig. 3 Primary T cell transduction confirm the DN4.99 TCR as lead CD1c-restricted mLPA-specific TCR to target acute leukemia. DN4.99, PZP8A6, and
DN4.2 TCRs were transduced into primary T cells. a Chimeric TCR expression on transduced (black histograms) and non-transduced primary polyclonal
T cells (white histograms) determined by labeling with anti-mouse TCRβ (mTCRβ) monoclonal antibody (mAb). b Endogenous human TCR expression in
chimeric TCR-transduced (black histograms) and non-transduced T cells (white histograms) determined at the same time point as in (a) by labeling with
anti-human TCRβ (hTCRβ) mAb. Dotted histograms represent Fluorescence-Minus-One (FMO) labeling control. Relative Fluorescence Intensity (RFI) was
calculated as the ratio between the intensity of labeling of the sample and control. c Recognition of THP-1-CD1c (black histograms) but not of THP-1-Wild-
Type (WT) cells (gray histograms) by human primary T cells 18 days after their transduction with the indicated chimeric TCRs, determined by measuring
the secreted IFN-γ in the supernatant of 2.5:1 Effector:Target ratio co-cultures. Data are represented as mean ± SD. Results are representative of 2 (for
PZP8A6 TCR-T cell and DN4.2 TCR-T cells) or 4 independent experiments (for DN4.99 TCR-T cells) with n = 3 independent replicates per experiment. *P
= 0.0245; ***P = 0.0003 DN4.99 TCR-T cells; ***P = 0.0005 PZP8A6 TCR-T cells; ****P < 0.0001 determined by Ordinary one-way ANOVA followed by
Tukey’s multiple comparison test.
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Fig. 4 DN4.99 TCR-T cells efficiently recognize and kill CD1c+ leukemia-cell lines. Primary T cells were transduced (DN4.99 TCR-T cells) or not-
transduced (T cells) with the lead DN4.99 TCR and assessed in vitro for the recognition and killing of CD1c-expressing acute leukemia or
lymphoblastoid cell lines. a CD1c expression (black histograms) on 7 different acute leukemia (THP-1, MOLM-13, K562, NALM-6, CCRF-SB, MOLT-4)
or lymphoblastoid (C1R) cell lines, as determined by flow cytometry measurement of labeling with anti-human CD1c monoclonal antibody (mAb).
White histograms represent labeling with isotype-matched control mAb. Relative Fluorescence Intensity (RFI) was calculated as the ratio between
intensity of labeling of the sample and control. b Recognition of CD1c-expressing acute leukemia or lymphoblastoid cell lines by DN4.99 TCR-
transduced or non-transduced primary T cells following 48 h of co-culture at a 1:1 Effector:Target ratio with either 20 μg/ml of blocking anti-CD1c mAb
(gray bars) or an equivalent concentration of mouse IgG1κ isotype control (black bars). IFN-γ secretion into supernatants was measured by ELISA.
Data are represented as mean ± SD. Results are representative of 2 (for CCRF-SB, MOLT-4 and C1R-CD1c) and 4 (for THP-1-CD1c, MOLM-13-CD1c,
K562-CD1c and NALM-6-CD1c) independent experiments with n = 3 replicates per experiments. ***P = 0.0001; **** P < 0.0001 determined by
Ordinary one-way ANOVA followed by Tukey’s multiple comparison test. c, d Representative flow cytometry analysis to assess killing of THP-1-CD1c
(c) and CCRF-SB (d) cells by DN4.99 TCR-T cells after 72 h of the same co-culture conditions of (b). e Killing of each target cell line in the same co-
cultures determined as shown in (c, d), expressed as an Elimination Index as described in Methods. Gray bars represent co-cultures with anti-CD1c
mAb, and black bars with the isotype control. Data are represented as mean ± SD. Results are representative of 2 (for K562-CD1c, CCRF-SB, MOLT-4
and C1R-CD1c) and 4 (for THP-1-CD1c, MOLM-13-CD1c and NALM-6-CD1c) independent experiments with n = 3 replicates per experiments. **P =
0.0071; ****P < 0.0001 determined by unpaired two-tailed Welch’s t-test.
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commonly observed upon transfer of human peptide-specific
TCR that cross-react with mouse peptide–MHC complexes25,
which was instead observed in mice receiving non-transduced
T cells (Supplementary Fig. 3f).
We then assessed the ability of DN4.99 TCR-T cells to inhibit the
growth of the more aggressive NALM-6 cell line in NSG mice. In
this second model, we assessed the efficacy and safety of multiple
transfers of DN4.99 TCR-T cells at 7 days intervals, to enhance the
control of this relatively more aggressive leukemia (Fig. 8a). NALM-
6-CD1c (5 × 105) cells were injected i.v. into NSG mice that, after
tumor engraftment confirmed by their serum luciferase levels, were
randomized into three groups and sub-lethally irradiated, followed
24 h later by the transfer i.v. of 1 × 107 DN4.99 TCR-T cells; 1 ×
107 T cells transduced with the chimeric TCR from the CD1c-
restricted T cell clone DL15A31, specific for an M. tuberculosis-
derived lipid and completely unable to react in vitro against CD1c-
expressing leukemia cells ± mLPA (Supplementary Fig. 4 and
ref. 10); or vehicle alone (Fig. 8a). NALM-6-CD1c B-ALL cells
engraft in the bone marrow of NSG mice, with the appearance of
circulating blasts as the tumor burden increased26. Here, we saw
that leukemia progression was significantly delayed in mice that
received DN4.99 TCR-T cells, compared to the two control groups
(Fig. 8b). A second transfer of DN4.99 TCR-T cells, performed
7 days after the first one, further significantly delayed leukemia
progression (Fig. 8b), as also shown by reduced frequency of
circulating blasts at day+17 from tumor injection (Fig. 8c). DN4.99
TCR-T cells were found in the bone marrow four days after the first
ACT (Fig. 8d), demonstrating tumor co-localization also in this
model. Similarly, DN4.99 TCR-T cell treatment significantly
prolonged the survival of tumor-bearing mice (Fig. 8e). At the
experimental endpoint, the DN4.99 TCR-T cell transfer resulted in
the survival of NALM-6 cells expressing lower levels of CD1c than
tumors of control mice (Fig. 8f), confirming the CD1c-dependent
mechanism of tumor recognition and the strong anti-leukemia
effect of this TCR.
Finally, we investigated the possibility of boosting the tumor-
specific response of DN4.99 TCR-T cells in leukemia-bearing
mice with an mLPA therapeutic immunization between T cell
treatments. We injected 5 × 104 highly aggressive MOLM-13-
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Fig. 5 DN4.99 TCR-T cells efficiently recognize and kill primary CD1c+ Acute Leukemia Blasts in vitro. Primary T cells were transduced with DN4.99
TCR (DN4.99 TCR-T cells), separated by cell sorting into CD4+ and CD8+ T cells, and mixed back again to generate a mixture of 70-80% CD8+ and 30-
20% CD4+ cells, which was assessed in vitro for the recognition and killing of CD1c-expressing primary circulating acute leukemia blasts. a Flow cytometry
detection of CD1c expression (black histograms) on ex vivo B-Acute Lymphoblastic Leukemia (B-ALL) and Acute Myeloid Leukemia (AML) blasts labeled
with anti-human CD1c monoclonal antibody (mAb). White histograms represent labeling with isotype-matched control mAb. Relative Fluorescence
Intensity (RFI) was calculated as the ratio between the intensity of labeling of sample and control. b Recognition of primary CD1c+ AML blasts by
CD8+/CD4+ DN4.99 TCR-T cells, co-cultured for 48 h at 10:1 or 5:1 Effector:Target (E:T) ratio with either 20 μg/ml of blocking anti-CD1c mAb or an
equivalent concentration of mouse IgG1κ isotype control. IFN-γ secretion into supernatants was measured by ELISA. c Representative killing of the target
leukemia B-ALL-11 blasts by CD8+/CD4+ DN4.99 TCR-T cells, determined by flow cytometry labeling after 48 h of the same co-cultures. d Killing of each
indicated primary blast by CD8+/CD4+ DN4.99 TCR-T cells of the same co-culture conditions of (b), expressed as % of killing, as described in Methods.
Gray bars represent co-cultures with anti-CD1c mAb, and black bars with the isotype control. Allogenic CD8+/CD4+ DN4.99 TCR-T cells were from 3
independent healthy donors. Data are represented as mean ± SD. **P = 0.003 determined by unpaired two-tailed t-test followed by Mann–Whitney test
(b). ****P < 0.0001 determined by Ordinary one-way ANOVA followed by Tukey’s multiple comparison test (d).
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them to sub-lethal irradiation, followed 24 h later by randomiza-
tion and i.v. injection of DN4.99 TCR-T cells or vehicle only. On
day 29, 5 × 105 human CD1c+ monocyte-derived dentritic cells
(moDCs) pre-loaded with mLPA were injected i.v. into all mice,
followed by further TCR-T cells/vehicle only injections on days
36 and 42 post-initiation (Fig. 9a). These antigen-loaded moDC
were intended to promote activation and expansion of DN4.99
TCR-T cells in vivo by acting as CD1c-expressing APCs, which
are otherwise lacking in mice, as they do not have group 1 CD1
genes. We found that the first adoptive T cell transfer (day 18
post-initiation) delayed leukemia progression up to day 24, after
which progression of these highly aggressive tumors resumed
(Fig. 9b inset). Immunization with mLPA-loaded moDCs (day
29) resulted in a deflection of the leukemia progression curve only
in the mice that had received DN4.99 TCR-T cells (Fig. 9b), and
was also associated with a significant increase in the frequency of
TCR-T cells (Fig. 9c), which probably contributed to delayed
tumor growth. The combination of multiple DN4.99 TCR-T cell
injections and mLPA-loaded moDC immunization resulted in
significantly increased survival compared to vehicle-only-treated
controls (Fig. 9d).
Collectively, these results highlight the efficacy of immunother-
apy combining ACT plus tumor antigen-specific vaccination and
confirmed the strong potential of a donor-unrestricted ACT
approach for acute leukemia with CD1c-retargeted T cells.
Discussion
We have shown that targeting T cells against tumor-related lipid
antigens presented by CD1c are a viable immunotherapy strategy
for hematological malignancies, which are driven by the patho-
logical counterpart of the cells that normally express CD1 group 1
molecules. This strategy is importantly different from adoptive
immunotherapy with T cells engineered to express TCRs specific
for MHC-presented peptides; rather, the approach we propose is
comparable with CAR-T cell therapy because it has no histo-
compatibility barriers, owing to the lack of CD1c polymorphism6.
Our strategy allows the generation of “universal” effector T cells
for a donor-unrestricted application of ACT to any patient
bearing CD1c-expressing leukemia: moreover, in an allogeneic
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Fig. 6 DN4.99 TCR-T cells do not recognize normal CD1c+ blood cells.
Primary DN4.99 TCR-transduced T (DN4.99 TCR-T) cells were assessed
for killing in vitro normal circulating CD1c+ cells. a–c CD19+ B cells (a),
CD14+ monocytes (b), and CD11c+ circulating dendritic cells (cDCs, c)
were sequentially purified from the peripheral blood of healthy donors.
Contour plots and histograms show the enrichment of each cell type and
their CD1c expression (black histograms), determined ex vivo by flow
cytometry labeling with the indicated monoclonal antibody (mAb). White
histograms represent labeling with isotype-matched control mAb. Relative
Fluorescence Intensity (RFI) was calculated as the ratio between the
intensity of labeling of sample and control. d There was not any killing of
primary B cells, monocytes and cDCs by DN4.99 TCR-T cells. T cells were
co-cultured for 72 h with B cells, monocytes, or cDCs at a 1:1 Effector:Target
(E:T) ratio, with either 20 μg/ml of blocking anti-CD1c mAb (gray bars),
isotype control (black bars), or synthetic methyl-lysophosphatidic acid
(mLPA; red bars), used as positive control. Target killing was determined by
flow cytometry labeling and expressed as Elimination Index. e There was
not any killing of primary B cells, monocytes and cDCs by DN4.99 TCR
CD8+/CD4+ T cells. T cell co-cultures with B cells, monocytes, or cDCs
and target killing assays were performed as described for primary leukemia
blasts. Gray bars represent co-cultures with anti-CD1c mAb, and black bars
with the isotype control. Note that DN4.99 TCR-T cells can only kill primary
monocytes and cDCs upon supplementation with the synthetic mLPA-
specific antigen. Data are represented as mean ± SD. **P = 0.0071; *** =
0.0001; not significant (ns) were determined by Ordinary one-way ANOVA
followed by Tukey’s multiple comparison test. Shown are results obtained
in independent experiments with n = 3 replicates/each displayed as
mean; (d) n = 4 experiments for cDCs + mLPA; 5 for B cells + mLPA,
monocytes + mLPA, cDCs + Isotype control and cDCs + anti-CD1c mAb;
and n = 6 for all the other conditions. e n = 2 for cDCs and n = 3 for B cells
and monocytes. Normal circulating CD1c+ cells were purified from different
healthy donors in each experiment.
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HSCT setting, the risk of GvHD should be minimized upon ACT
given the absence of CD1c on parenchymatous tissues.
Group 1 CD1-restricted T cells effectively extend the family of
immune effectors recognizing non-polymorphic antigen-pre-
senting molecules or ligands whose TCRs can be exploited to
generate unrestricted antitumor effector cells. Our strategy pro-
vides additional treatment options to the current arsenal of TCR-
and CAR-T cells, particularly for AML, where no CAR has been
yet approved due to major remaining challenges, including the
off-tumor expression of currently identified CAR targets (CD33,
CD34, CD123, FLT3)27, and is broadly applicable to either adult
or pediatric B-ALL and AML patients owing to their common
expression of CD1c molecules on blasts. In addition, any CD1c-
expressing hematological malignancies, such as T-ALL and
DLBCL, may also become possible therapeutic targets.
We provide preclinical data that show how primary human
T cells from a range of healthy donors can be engineered to
express a CD1c-restricted, mLPA-specific TCR and used for
effective adoptive immunotherapy of acute leukemia in mice,
without any clear side-effects assessable within the limitations of
human xenograft models in immunodeficient animals. A first
criterion in the development of such an approach is the ability to
generate homogenous anti-leukemia T cell populations pre-
ferentially expressing the transduced recombinant TCRs; this
aims at enhancing the therapeutic index of the ACT strategy,
while reducing its toxicity by minimizing off-target recognition,
alloreactivity, and GvHD risks28. Here, we achieved this by
generating chimeric molecules bearing the human TCR Vα and
Vβ regions linked to the mouse C domains, which have two key
advantages: they reduce the risk of potentially harmful mispairing
between the endogenous and exogenous TCR chains29–31; and
they increase the expression of the transduced TCR based on the
preferential pairing of mouse C regions with the human CD3ζ
chain, at the expense of the endogenous molecules12,31. The
selected chimeric DN4.99 TCR exhibited the greatest ability to
compete with the endogenous TCRs in transduced T cells, sug-
gesting that it behaves as a “strong” TCR with intrinsic properties
that favor its surface expression31,32. Notably, for clinical appli-
cations, mouse C regions do not seem particularly immunogenic
when transferred into man: when 26 cancer patients were treated
with autologous T cells engineered with a fully mouse tumor-
specific TCR, none developed antibodies against the mouse C
domain, and antibodies against the mouse V regions were
detected in only 6 patients33. Nonetheless, additional strategies to
prevent GvHD by the TCR-transduced T cells could be envisaged,
such as knocking-down endogenous TCR expression using
genome-editing approaches34, or transferring the antitumor TCR
into the unconventional iNKT, MR1- or γδ-T cell subsets that do
not elicit GvHD upon allogeneic transfer because they are
restricted to non-polymorphic molecules and express TCRs with
strong intra-chain physical constraints, thereby minimizing
mispairing with endogenous TCR chains35,36.
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Fig. 7 In vivo anti-leukemia efficacy of DN4.99 TCR-T cells against THP-1-CD1c-tumor cells. DN4.99 TCR-transduced T (DN4.99 TCR-T) cells and non-
transduced T cells (T cells), all at 70% CD8+/30% CD4+, were assessed for the ability to control the progression of THP-1-CD1c acute leukemia in vivo.
a NOD.Cg-Prkdcscid IL- 2rgtm1Wjl/SzJ (NSG) mice (n = 15) received intravenous (i.v.) injection of 106 THP-1-CD1c cells co-expressing secreted LUCIA
luciferase. Three weeks later the mice were sub-lethally irradiated, followed 24 h later by the transfer of 107 DN4.99 TCR-T cells (red lines/dots), T cells
(black lines/squares), or vehicle (gray line/triangles). n = 5 mice/group. b Tumor progression was monitored weekly in blood collections by
bioluminescence assay and depicted as the Relative Light Unit (RLU) detected at each time point. Data are represented as mean ± SEM. ****P < 0.0001
determined on AUC by Ordinary one-way ANOVA followed by Tukey’s multiple comparison test. c Kaplan–Meier survival curves show a significant
increase in the survival of mice receiving DN4.99 TCR-T cells compared to the control groups. *P = 0.0368 with T cells; *P = 0.0274 with vehicle
determined by log-rank (Mantel–Cox) test. d Reduced endpoint liver weight in mice receiving DN4.99 TCR-T cells (red dots) compared to the control
groups (non-injected aged-match NSG mice: white dots; mice receiving: T cells, black squares; vehicle, gray triangles), determined at sacrifice (day +46).
Data are represented as mean ± SD. *P = 0.01557 with T cells; *P = 0.0224 vehicle determined by Ordinary one-way ANOVA followed by Tukey’s multiple
comparison test. e Persistence of DN4.99 TCR-T cells in the liver of mice, determined by flow cytometry at sacrifice. DN4.99 TCR-T cells and THP1-CD1c
leukemia cells were identified by mouse (m)TCRβ, human CD3, and GFP expression, respectively, among gated mouse CD45- mononuclear hepatic cells.
Results are representative of 5 independent experiments with independent T cell lines giving comparable results.
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The DN4.99 TCR-T cells specifically recognized and killed not
only CD1c-expressing acute myeloid and lymphoblastic
leukemia-cell lines, but also primary circulating AML and B-ALL
blasts in vitro. However, the ACT strategy we envisage involves
the use of a TCR which is autoreactive and therefore potentially
harmful. Thus, a second criterion for its development is the
strong specificity of the lead DN4.99 TCR for self-antigens highly
enriched in cancer cells, compared to normal tissues. The
recognition of CD1c+ leukemic cells by T cell engineered with the
selected lead DN4.99 TCR was indeed increased by the addition
of synthetic mLPA, which suggests strong leukemia antigen-
specificity. Furthermore, one of the two CD1c self-reactive TCRs
that did not recognize CD1c+ target cells, the P8E3 TCR, shared
the same Vα and Vβ genes with the highly reactive DN4.99 TCR,
hinting to a critical role of the CDR3 regions for the recognition
of the mLPA–CD1c complex. This cumulative evidence strongly
suggests that the selected TCR does not directly recognize CD1c,
but depends rather on the association of mLPA with CD1c to
react. Given that mLPA is highly enriched in malignant cells
compared to normal10, the requirement for mLPA presentation
by CD1c adds another layer of protection and again favors the
proposed ACT approach. Consistent with the requirement for
mLPA–CD1c complexes to stimulate the lead DN4.99 TCR, and
with the need for the self-lipid antigen10, normal circulating
CD1c-expressing blood cells (B cells, monocytes, cDCs) were not
killed by the transduced T cells, even at a high 5:1 E:T ratio,
unless monocytes or DCs were artificially pre-loaded with mLPA.
In normal conditions, therefore, the adoptively transferred
DN4.99 TCR-T cells should spare normal cells, unlike CD19
CAR-T cell therapy which causes B cell aplasia37, underscoring
the likely safety of ACT targeting mLPA–CD1c complexes.
Nevertheless, the safety of the engineered T cells could be further
increased by introducing suicide or antibody-targeting genes into
the TCR-expressing lentiviral coding vector, a strategy already
exploited in TCR and CAR gene therapy38–41.
The unique availability of a defined leukemia-enriched self-
lipid antigen also provides us with the opportunity to boost the
engineered T cell response with mLPA-containing vaccines, in
turn stimulating and enhancing the efficacy of the CD1c-targeting
ACT strategy. We used human moDCs as vehicles for synthetic
mLPA as they can also provide high levels of CD1c expression
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Fig. 8 In vivo anti-leukemia efficacy of DN4.99 TCR-T cells against CD1c+ acute leukemia NALM-6. DN4.99 TCR-transduced T (DN4.99 TCR-T) cells
restrict NALM-6-CD1c leukemia progression in vivo. a NOD.Cg-Prkdcscid IL- 2rgtm1Wjl/SzJ (NSG) mice (n = 30) received intravenous (i.v.) injection of
5 × 105 NALM-6 CD1c co-expressing secreted LUCIA luciferase. Two days later, the mice were sub-lethally irradiated, followed 24 h later by the transfer of
107 primary 70% CD8+/30% CD4+ DN4.99 TCR-T cells (red lines/dots), control T cells (black line/squares) transduced with the CD1c-restricted,
mycobacterial lipid-specific DL15A31 TCR (DL153A1 TCR-T cells; Supplementary Fig. 4 and ref. 10) or vehicle (gray lines/triangles). n = 10 mice/group.
After 7 days, DN4.99 TCR-T cells were transferred a second time, without prior irradiation, into the same mice. b Tumor progression was monitored in
peripheral blood by a bioluminescence assay. RLU, relative light unit. Data are represented as mean ± SEM. ****P < 0.0001 determined on AUC by Ordinary
one-way ANOVA followed by Tukey’s multiple comparison test. c DN4.99 TCR-T cells reduce the number of circulating NALM-6-CD1c leukemia cells. The
frequency of human CD19+ tumor cells was determined by flow cytometry in the blood of mice at day+17 from tumor injection. The percentage of the
tumor cells was normalized based on the percentage of mouse CD45- cells. *P = 0.0101; ***P = 0.0003; ****P < 0.0001. d Presence of DN4.99 TCR-T cells
in the bone marrow of NALM-6 CD1c bearing mice, determined by flow cytometry 4 days after their adoptive transfer. DN4.99 TCR-T cells were identified
as mouse (m)TCRb+ cells in the human (h)CD45+ mouse (m)CD45- cells. e Kaplan-Meier survival curves show a significant increase in the survival of
mice receiving DN4.99 TCR-T cells compared to control groups. **P = 0.0014 determined by log-rank (Mantel–Cox) test. f Reduced CD1c expression on
NALM-6-CD1c cells that survive DN4.99 TCR-T cell, as determined by flow cytometry labeling (MFI, Mean Fluorescence Intensity) of human CD19+
NALM-6-CD1c cells in the circulation at day+17 from tumor injection. **P = 0.0015; ****P < 0.0001. Data in (c) and (f) are represented as mean ± SD and
P-values were determined by unpaired two-tailed t test followed by Mann–Whitney test. Results are representative of 3 independent experiments with
independent T cell lines giving comparable results.
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CD1 expression, this induced a marked increase in numbers of
the transferred DN4.99 TCR-T cells and in their anti-leukemia
functions. This vaccine strategy has already been approved for use
in patients42, and it is a suitable option to improve our ACT
strategy. The presence of endogenous CD1c-expressing APCs in
man may also support a cell-free formulation of an mLPA vaccine
for its direct delivery in vivo. However, this approach should be
carefully evaluated because it may associate with unwanted
potential on-target/off-tumor elimination of the endogenous
CD1c+ APCs presenting mLPA to engineered T cells.
A further advantageous feature of the DN4.99 TCR is its
derivation from a CD4/CD8 double negative T cell clone, which
enables its coreceptor-independent CD1c recognition and allows
it to be used to efficiently redirect both CD8+ and CD4+ trans-
duced T cells against CD1c+ leukemia targets. The following
evidence from CAR-T cell therapy19 and preclinical studies
suggesting that CD4+ CAR-T cells, upon tumor recognition,
produce IL-2 that augments CD8+ CAR-T cell proliferation,
survival, and antitumor lytic activity43, we also generated 70%
CD8+/30% CD4+ mixture of DN4.99 TCR-T cells that was
effective in vivo. Future studies could explore a range of relative
ratios between the two subsets in order to understand the optimal
point for antitumor efficacy.
Finally, our data establish the feasibility and preclinical safety
of single, as well as repeated, administration of DN4.99 TCR-T
cells to control leukemia in vivo in three distinct cancer xenograft
models. In all models, we saw that transferred T cells migrated to
the tumor site, and all models showed clear clinical benefit from
transfer of DN4.99 TCR-T cells. Interestingly, the tumor cells that
survived in the mice had a lower expression of CD1c compared to
remaining cells in the control groups, supporting the CD1c-
dependent mechanism of tumor recognition and the strong anti-
leukemia effect of this TCR, while also suggesting a possible
mechanism of immune escape relying on the loss/reduction of the
target of the immune response. Since the CD1c gene is identical
on both human chromosomes 16, unlike most HLA alleles on
chromosome 6, we hypothesize that the loss of one allele might
cause a reduction in CD1c expression but not its complete loss on
the leukemia surface, preserving its recognition by DN4.99 TCR-
T cells. It is also possible that the physiological expression of
CD1c in blasts might be epigenetically or transcriptionally regu-
lated. It will be critical to unravel these largely unknown
mechanisms in order to define possible pharmacological inter-
ventions to sustain CD1c expression specifically in blasts.
Nevertheless, the immune evasion phenomenon is frequently
observed in other current ACTs that show clinical efficacy, such
as the B-ALL escape from CD19 CAR-T cells via CD19
downregulation44, or the HLA loss that occurs in acute leuke-
mia relapse resulting from allogeneic T cell immune pressure
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Fig. 9 mLPA-antigen cellular immunization sustains the in vivo anti-leukemia efficacy of DN4.99 TCR-T cells against CD1c+ acute leukemia MOLM-13.
a DN4.99 TCR-transduced T (DN4.99 TCR-T) cells restrict MOLM-13 leukemia progression in vivo. NOD.Cg-Prkdcscid IL- 2rgtm1Wjl/SzJ (NSG) mice
(n = 10) received intravenous (i.v.) injection of 5 × 104 MOLM-13-CD1c cells co-expressing secreted LUCIA luciferase. After 17 days, mice were sub-
lethally irradiated, followed 24 h later by the transfer of 107 DN4.99 TCR-T cells (red lines/dots) or vehicle (gray lines/triangles). n = 5 mice/group. After
2 weeks, all mice received i.v. 5 × 105 monocyte-derived Dendritic Cells (moDCs) loaded with methyl-lysophosphatidic acid (mLPA), followed, only in the
mice the had originally received the first T cell transfer, by two subsequent transfers of 107 DN4.99 TCR-T cells one week apart. b Tumor progression was
monitored in peripheral blood by a bioluminescence assay. RLU, Relative Light Unit. c DN4.99 TCR-T cell expansion upon i.v. injection of mLPA-loaded
moDCs into MOLM-13-CD1c tumor-bearing mice, determined as the percentage of human T cells in the peripheral blood of mice by flow cytometry
labeling with anti-mouse CD45 and anti-human CD3 monoclonal antibody. T cell frequency was normalized based on the percentage of mouse CD45-
cells. Data are represented as mean ± SD. *P = 0.0467; ***P = 0.0002 determined by Ordinary one-way ANOVA followed by Tukey’s multiple comparison
test. n = 5 mice at day +21, +26, and +37; n = 2 mice at day +42. d Kaplan–Meier survival curves show a significant increase in the survival of mice
receiving DN4.99 TCR-T cells compared to control groups. **P = 0.002 determined by log-rank (Mantel–Cox) test. Results are representative of 2
independent experiments with independent T cell lines giving comparable results.
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studies are warranted to improve the DN4.99 TCR affinity for
the mLPA–CD1c complex, or to pharmacologically sustain
CD1c expression on malignant cells, in order to target cancer
cells expressing low CD1c levels and prevent/minimize possible
immune evasion. Furthermore, co-targeting CD1c with other
already available leukemia-restricted antigens could also mini-
mize the antigen loss leading to immune evasion.
In conclusion, our results support the use of mLPA-specific
CD1c-restricted T cell as an attractive option for adoptive
immunotherapy of leukemia across MHC barriers.
Methods
Animal care. All mouse experiments performed in this study were approved by the
San Raffaele Scientific Institute IACUC (678 and 1072) and by the Italian Ministry
of Health (Rome, Italy) and were conducted in compliance with national laws and
policies. Mice were housed in a Specific and Opportunistic Pathogen Free (SOPF)
with optimize and controlled conditions (12-h light/12-h dark cycle, temperature
of 22 °C ± 2 °C, and relative humidity of 55% ± 5%), and monitored daily for health
status and weight loss. Blood was collected once (for the THP-1 model) or twice
(for NALM-6 and MOLM-13 models) per week to assess tumor progression. The
terminal disease stage was determined when the luciferase signal in the blood
reached 2–3 × 106 relative light unit (RLU) for THP-1 and NALM-6, and 1–2 × 105
RLU for MOLM-13. Mice were euthanized before study termination if they showed
>20% body weight loss from their starting weight, or other distress signs (scruffy
coat, altered postured, or reduced mobility).
Human samples. Peripheral blood containing primary leukemia blasts was
obtained from adult patients (AML-48, AML-32, AML-45, AML-34, AML-28,
AML-42, AML-44, San Raffaele Leukemia Biobank) following written informed
consent, and from pediatric patients (B-ALL-31, Fondazione IRCCS Policlinico San
Matteo Pavia, Italy; AML-11 M. Tettamanti Research Center, University of Milano-
Bicocca, Monza, Italy) with written informed consent from their parents, and in
agreement with the declaration of Helsinki. The study protocol “CD1TARGET”
was approved by the San Raffaele Ethics Committee on November 6th, 2018.
Primary leukemia samples were obtained from peripheral blood of male and female
patients at diagnosis. The age range of adult patients was between 25 and 88 years,
while that of pediatric patients was 3–10 years. Patients were recruited at diagnosis,
with a percentage of circulating blasts between 60 and 97% of leukocytes to
minimize manipulation following density gradient centrifugation. Moreover, only
patients with CD1c expression on blasts with Relative fluorescence intensity ≥ 2.5
were recruited.
T cells, B cells, monocytes, and cDCs were purified from PBMCs isolated from
buffy coats of anonymous healthy volunteers obtained after written informed
consent.
In silico measurement of CD1 gene expression in leukemia datasets. The
analyses of gene expression data from publicly available human leukemia datasets
were performed in R (version 3.4.4) using Bioconductor libraries of BioC 3.6 and R
statistical packages. Microarray raw data were download as CEL files from Gene
Expression Omnibus using the GEOquery (v. 2.46) package46. The raw intensity
signals were extracted from CEL files and normalized using the robust multi-array
average procedure RMA47 of the affy (v. 1.56) package. Specifically, probe fluor-
escence intensities were background adjusted, normalized using quantile normal-
ization, and log2 expression values calculated using median polish summarization
and the custom chip definition files from Brain Array (v. 20.0, http://brainarray.
mbni.med.umich.edu/Brainarray/Database/CustomCDF) for human Affymetrix
arrays based on Entrez genes (i.de., hgu133ahsentrezgcdf, hgu133bhsentrezgcdf,
hgu133plus2hsentrez and hugene10sthsentrezg). When multiple array versions
were used in a single dataset, e.g. GSE12417, only common probes across platforms
were retained and batch correction was performed using the ComBat function of
the SVA (v. 3.26.0) package48 with the platform version as batch covariate. Raw
data for the TCGA-LAML dataset were downloaded as raw counts from the TCGA
repository using the TCGAbiolinks R package (v. 2.15;49. Data normalization was
performed using the edgeR R package (v. 3.20.0;50. Specifically, raw counts were
normalized to counts per million mapped reads (CPM) and only genes with a CPM
greater than 1 in at least 3 samples were retained. Differential analysis of CD1c
expression between each TCGA tumor and its corresponding normal tissue from
GTEx was performed using the Gene Expression Profiling Interactive Analysis web
tool (GEPIA v.1.0; http://gepia.cancer-pku.cn;51). In GEPIA, gene expression levels
of samples from the two projects were re-computed using a uniform pipeline.
CD1c expression was considered significant at P ≤ 0.01 in a one-way ANOVA.
Lentivirus construction and production. The sequences encoding the chimeric
TCRs were synthetized by GeneArt. A Kozak consensus sequence (accgcc) was
inserted 5′ to the ATG to optimize the translational starting site, and a STOP codon
was inserted at the 3′ of the Cβ. The cDNAs of the α and β TCRs were linked by the
2A peptide and subcloned into the LV pHRSIN-Bx-IRES-EmGFP (kindly provided
by Dr. V. Cerundolo, University of Oxford), in which the TCR-coding genes can be
followed by IRES and the GFP-coding sequence. The cDNA encoding CD1c was
cloned by PCR with specific primers (listed in Supplementary Table 3) and inserted
into the LV pHRSIN-Bx-IRES-EmGFP. The production of the lentiviral vectors
was performed as described previously52 by the transient transfection of 293T cell
line (ATCC) using a second-generation lentiviral vector system. Subconfluent
293T, seeded in a 15 cm dish in IMDM medium (Lonza) supplemented with 10%
heat-inactivated FBS (EuroClone), 10U/ml penicillin and streptomycin (Lonza),
were transfected by Ca2PO4 method with the packaging plasmids (12 μg pMD2.
VSV-G, 16.25 μg pCMVΔR8.74, 6.25 μg pRSV-rev) and 32 μg of transfer vector
plasmid. After 16 h medium was replaced and 30 h later the supernatant containing
the LV were collected and concentrate by ultracentrifugation at 20,000 rpm for 2 h.
Leukemia-cell lines. Cell lines were cultured in RPMI 1640-GlutaMAX (Gibco)
complete medium (supplemented with 10% heat-inactivated FBS (EuroClone),
10U/ml penicillin and streptomycin (Lonza), 1% non-essential amino acids 100x
(Gibco), 1 mM sodium-pyruvate (Gibco), and 50 μM 2-mercaptoethanol (Gibco).
Disruption of B2M gene in Jurkat 76 cells (kindly provided by Prof. H.J. Stauss,
University College London) was performed by CRISPR/Cas9 technology with Dr.
A. Lombardo (IRCCS San Raffaele Scientific Institute). Jurkat 76 β2m- cells were
transduced with LV encoding the CD1c-restricted TCRs and GFP at a multiplicity
of infection (MOI) of 100. The following leukemia-cell lines were used: THP-1-
WT, K562-WT, MOLT-4, (American Type Culture Collection, Manassas, VA),
K562-CD1c8 (provided by Prof. D.B. Moody, Brigham and Women’s Hospital,
Harvard Medical School, Boston), C1R-CD1c (provided by Prof. S. Porcelli, Albert
Einstein College of Medicine, New York) and MOLM-13 (provided by Dr. R.
Bernardi, San Raffaele Scientific Institute), THP-1-CD1c, CCRF-SB, NALM-6 and
THP-1 expressing the Gaussia LUCIA. MOLM-13 cells were transduced with a LV
encoding the secreted Gaussia Luciferase Lucia and the LNGFR selection marker.
Gaussia Luciferase Lucia-expressing THP-1, NALM-6, and MOLM-13 cells
were transduced with a LV encoding CD1c (MOI:100). All cells were maintained at
37 °C in a humidified atmosphere containing 5% CO2.
TCR-transduced Jurkat 76 β2m- cell assays. 105 TCR-JK cells were co-cultured
overnight at different E:T ratios with the indicated leukemia-cell lines (THP-1,
2.5:1 E:T ratio; or K562, 1:1 E:T ratio) that had been pre-loaded or not with
different concentrations of mLPA for 4 hours at 37 °C. TCR-JK activation
was measured by CD69 expression level using flow cytometry (expressed as
median fluorescence intensity, MFI). The mLPA EC50 for each transduced TCRs
(Fig. 2e) were calculated using PRISM_V8 software (GraphPad), which plot the
MFI of CD69 against the mLPA concentration in log scale, generating a
sigmoidal curve.
Primary T cell Culture, Transduction and Stimulation. Peripheral blood
mononuclear cells were isolated by Ficoll-Paque (GE HealthCare) density gra-
dient centrifugation of buffy coats from healthy volunteers. CD8+ and CD4+
T cells were isolated using CD4 Isolation Kit (Miltenyi Biotec, Cat# 130-096-
533) as shown in Supplementary Fig. 3a. T cells were activated with Dynabeads
human T-Activator CD3/CD28 (Thermofisher, Cat# 11131D) at a 3:1 bead:cell
ratio for 2 days, then transduced with the LV encoding the indicated TCR
(MOI:100) and further expanded until day 18-20 before use (or cryopreserva-
tion). When indicated CD8+ and CD4+ T cells were combined to have 70% CD8
+/30% CD4+ DN4.99 TCR-T cells. T cells were activated and cultured in RPMI
1640-GlutaMAX medium supplemented with 10% heat-inactivated FBS, 10U/ml
penicillin and streptomycin, 1% non-essential amino acids 100X, 1 mM sodium-
pyruvate, 50 μM 2-mercaptoethanol, and 5 ng/ml rhIL-7 + rhIL-15 (R&D),
approximatively 22 × 102 IU/ml each.
TCR-transduced T cell assays. TCR-transduced and non-transduced T cells were
co-cultured with leukemia-cell lines, primary leukemia blasts, or primary circu-
lating B cells, monocytes, or cDCs at the indicated E:T ratios. Normal CD1c+ APCs
were subsequently purified from peripheral blood of healthy volunteers using
immunomagnetic beads according to the manufacturer’s protocols: first we purified
monocytes with anti-CD14 microbeads (Miltenyi Biotec, Cat# 130-050-201); then
we purified cDCs with anti-CD11c-APC mAb (diluted 1:100; Biolegend, clone 3.9)
and anti-APC microbeads (Miltenyi Biotec, Cat# 130-090-855); finally, we purified
B cells with anti-CD19 microbeads (Miltenyi Biotec, Cat# 130-050-301). Cultures
also included either 20 μg/ml of anti-CD1c antibody (clone M241; Santa Cruz
Biotechnology Inc.) or equivalent concentration of mouse IgG1κ isotype control
(clone 107.3; BD). Where indicated, T cells were combined to obtain 70-80% CD8+
and 20–30% CD4+ cell mixtures. Supernatants were collected after 48 h to quantify
IFN-γ release by enzyme-linked immunosorbent assay (ELISA). ELISA plates
(Maxisorp, NUNC) were coated with mouse anti-human IFN-γ mAb (Invitrogen,
diluted 1:1000, clone 2G1). After blocking with PBS1x-5% BSA, samples were
added for 1 h and subsequently incubated with the mouse anti-human IFN-γ
biotin-labeled mAb (Invitrogen, diluted 1:1000, clone B133.5). Signal was revealed
by streptavidin-bound horseradish peroxidase (diluted 1:30000, Thermo Scientific)
and TMB substrate (Sigma). The colorimetric reaction was stopped by the addition
of 18% sulfuric acid and the absorbance at 450 nm optical density was read with
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the iMark Microplate Reader (BIO-RAD, Microplate Manager Software v6.3) at
450 nm optical density and cytokine concentration was calculated based on the
standard curve.
To assess killing, after 48 h (leukemia blast targets) or 72 h (leukemia-cell line
targets) of co-culture cells were counted, and T and target cells were discriminated
by flow cytometry analysis with cell-type-specific markers. The elimination index
(EI) was calculated as 1−(number of residual target cells in the presence of
transduced T cells/number of residual target cells in the presence of non-
transduced T cells)*100. Percentage of killing was calculated as 1−(number of
residual target cells in presence of transduced T cells/number of residual target cells
alone)*100.
Flow cytometry analysis. CD1c expression was detected with anti-CD1c PE mAb
from Santa Cruz Biotechnology Inc. (clone L161, diluted 1:20), or with anti-CD1c
PE from BioLegend (clone L161, diluted 1:50) for the B-ALL-31. The isotype-
matched control mAb used for this labeling was the PE mouse IgG1, κ isotype
control (clone MOPC-21, BD, diluted 1:20).
Human leukemia cells were identified using the following anti-human mAbs
(all from BioLegend unless otherwise stated): CD45 PE/Cy7 (clone HI30, diluted
1:200); CD33 FITC (clone HIM3-4, diluted 1:100), PE or APC (clone WM53,
diluted 1:100); CD34 FITC or APC (clone 581, diluted 1:100); CD19 FITC, PE,
PerCP/Cy5.5 or APC/Cy7 (clone HIB19, diluted 1:100); CD10 APC (clone HI10a,
diluted 1:100), and CD1d-PE (clone 42.1, BD, diluted 1:20).
T cells were labeled with the following mAbs (all from BioLegend unless
otherwise stated): anti-mouse TCRβ chain PE, PerCP/Cy5.5 or APC/Cy7 (clone
H57-597, diluted 1:100); and anti-human TCRα/β-APC (clone IP26, diluted 1:20);
CD3 FITC, PerCP/Cy5.5, PE/Cy7, APC or APC/Cy7 (clone HIT3a, diluted 1:100);
CD4 FITC, PE/Cy7, APC (clone RPA-T4, diluted 1:100) or V500 (clone RPA-T4,
BD, diluted 1:100); CD8 PE, PE-Cy7, APC or APC/Cy7 (clone SK1, diluted 1:100);
CD69 APC (clone FN50, diluted 1:100); HLA-ABC APC (clone W6/32, diluted
1:100); β2m PE (clone 2M2, diluted 1:50); CD62L PE/Cy7 (clone DREG-56, diluted
1:100); CD54RA FITC (clone HI100, diluted 1:50); CCR7 PE (clone G043H7,
diluted 1:50); CD95 PE (clone DX2, diluted 1:100).
Mouse cells were detected with anti-mouse CD45 APC/Cy7 (clone 30-F11,
BioLegend, diluted 1:100) or V500 (clone 30-F1, BD, diluted 1:50).
Circulating human B cells, monocytes, and DCs were identified using the
following mAbs (all from BioLegend): anti-human CD19 FITC, PE or PerCP/
Cy5.5 (clone HIB19, diluted 1:100), CD20-PE/Cy7 (clone 2H7, diluted 1:100),
CD14-PerCP/Cy5.5 (clone M5E2, diluted 1:100), and CD11c-APC (clone 3.9,
diluted 1:100). Viable and dead cells were discriminated with DAPI staining.
Samples were acquired on a FACS Canto II cell analyzer (BD, FACSDiva v8.0.2)
and all data were analyzed with FlowJo_V10 software (BD). All gating strategies
are shown in Supplementary Figs. 5 and 6. RFI (relative fluorescence intensity)
was calculated as the ratio between the MFI of sample and control labeling
(isotype-matched control mAb or fluorescence-minus-one (FMO) labeling
control), unless otherwise stated.
Human leukemia xenograft models. CD1c and Lucia luciferase-expressing THP-
1 (1 × 106/mouse), NALM-6 (5 × 105/mouse), or MOLM-13 (5 × 104/mouse)
cells22–24 were injected intravenously into 8-week-old male NOD.Cg-Prkdcscid IL-
2rgtm1Wjl/SzJ (NSG) mice (Charles River). Tumor progression was monitored
once (THP-1) or twice a week (NALM and MOLM-13) by assessing serum secreted
Lucia luciferase bioluminescence, quantified with the QUANTI-Luc detection
reagent (InvivoGen, rep-qlc1) using a luminometer Mithras (BertholdTech, Mik-
roWin 2000 v4.41), and expressed as Relative Light Unit (RLU), according to the
manufacturer’s instructions. At tumor engraftment, confirmed by the presence of
detectable serum luciferase level, mice were sub-lethally irradiated (175 cGy), and
24 h later were randomized to receive an intravenous injection of 1 × 107 70% CD8
+/30% CD4+ TCR-transduced T cells (DN4.99 TCR-T or DL15A31 TCR-T), non-
transduced T cells (T cells), or vehicle alone (PBS1x). T and leukemia-cell
expansion in mouse blood was monitored weekly by flow cytometry. MoDCs were
differentiated in vitro from purified CD14+ monocytes, that were cultured in RPMI
1640-GlutaMAX medium supplemented with 10% heat-inactivated FBS, 10U/ml
penicillin in the presence of 50 ng/ml GM-CSF and 20 ng/ml IL-4 (Peprotech) for
6 days as described53.
Mice were sacrificed when tumor growth reached the threshold value of 2–3 ×
106 RLU for THP-1 and NALM-6, 1–2 × 105 RLU for MOLM-13, or when
manifesting signs of suffering. The area under the curve (AUC) describing the
kinetics of tumor growth was calculated for each mouse, and values derived from
each group of animals were statistically compared.
Statistics. All statistical analyses were performed with Prism_V8 Software
(GraphPad). Data are shown as Mean ± SD or shown as ± SEM with at least n = 3
replicates as indicated in the figure legends. All statistical tests used are indicated in
the figure legend corresponding to each specific experiments. Comparisons were
made using the unpaired two-tailed t-test between two group comparison or the
one-way ANOVA test followed by Tukey’s multiple for three or more groups.
Animal survival data were analyzed using log-rank (Mantel–Cox). Differences with
a P value < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available within the paper and its
supplementary information files or from the corresponding authors upon reasonable
request. Microarray raw gene expression data (.CEL files) of all series listed in
Supplementary Table 1 are available in Gene Expression Omnibus (https://www.ncbi.
nlm.nih.gov/geo/). Raw data of the TCGA datasets are freely accessible at TCGA (https://
www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) and they
have been download from the repository using the TCGAbiolinks R package. The
primary accession codes and hyperlinks of GEO and TCGA datasets referred to in this
manuscript are listed in Supplementary Table 1. Source data for all figures are provided
within the paper, except for Fig. 1c since the publicly available online tool utilized to
generate the graphs (http://gepia.cancer-pku.cn, as indicated in methods) does not make
them available. Source data are provided with this paper.
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